Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis

Therapeutic Apheresis and Dialysis

Volumn 14, Issue 2, 2010, Pages 153-160

  Liu, Jun Feng ^a   Wang, Wei Xin ^a   Xue, Jun ^a   Zhao, Chong Bo ^a   You, Huai Zhou ^a   Lu, Jia Hong ^a   Gu, Yong ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Double filtration plasmapheresis; Immunoadsorption; Immunoglobulin; Late onset myasthenia gravis; Titin antibody

Indexed keywords

AUTOANTIBODY; CHOLINERGIC RECEPTOR ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; PREDNISOLONE; PRESYNAPTIC MEMBRANE ANTIBODY; TITIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANAPHYLAXIS; ANTIBODY BLOOD LEVEL; ARTICLE; ASSISTED VENTILATION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE FILTRATION PLASMAPHERESIS; FEMALE; HEMATOMA; HUMAN; HYPOTENSION; IMMUNOADSORPTION; INTERMETHOD COMPARISON; LENGTH OF STAY; MALE; MYASTHENIA GRAVIS; OUTCOME ASSESSMENT; PLASMAPHERESIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; QUANTITATIVE MYASTHENIA GRAVIS SCORE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT DURATION; VOMITING;

AGE OF ONSET; AUTOANTIBODIES; FEMALE; FILTRATION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOSORBENT TECHNIQUES; LENGTH OF STAY; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; PLASMAPHERESIS; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 77950223695     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2009.00751.x     Document Type: Article

References (44)

1. Gold R, Schneider-Gold C. Current and future standards in treatment of myasthenia gravis. Neurotherapeutics 2008 5 : 535 541.
2. Flachenecker P. Epidemiology of neuroimmunological diseases. J Neurol 2006 253 (Suppl. 5 V2 8.
3. Phillips LH. The epidemiology of myasthenia gravis. Semin Neurol 2004 24 : 17 20.
4. Al-Moallem MA, Alkali NH, Hakami MA, Zaidan RM. Myasthenia gravis: presentation and outcome in 104 patients managed in a single institution. Ann Saudi Med 2008 28 : 341 345.
5. Newsom-Davis J, Vincent A, Willcox N. Acetylcholine receptor antibody: clinical and experimental aspects. Ciba Found Symp 1982 90 : 225 247.
6. Aarli JA. Myasthenia gravis in the elderly: is it different? Ann N Y Acad Sci 2008 1132 : 238 243.
7. Aarli JA. Titin, thymoma, and myasthenia gravis. Arch Neurol 2001 58 : 869 870.
8. Kawaguchi N, Kuwabara S et al. Effects of thymectomy on late-onset myasthenia gravis without thymoma. Clin Neurol Neurosurg 2007 109 : 858 861.
9. Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2008 CD002277
10. Illa I. IVIg in myasthenia gravis, Lambert Eaton myasthenicsyndrome and inflammatory myopathies current status. J Neurol 2005;252(Suppl. 1):I14-I18.
11. Gajdos P, Chevret S. Treatment of myasthenia gravis acute exacerbations with intravenous immunoglobulin. Ann N Y Acad Sci 2008 1132 : 271 275.
12. Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 2007 68 : 837 841.
13. Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev 2002 CD002275.
14. Szczepiorkowski ZM, Shaz BH, Bandarenko N, Winters JL. The new approach to assignment of ASFA categories-introduction to fourth special issue: clinical applications of therapeutic apheresis. J Clin Apheresis 2007 22 : 96 105.
15. Sarkar BK, Sengupta P, Sarkar UN. Surgical outcome in thymic tumors with myasthenia gravis after plasmapheresis - a comparative study. Interact Cardiovasc Thorac Surg 2008 7 : 1007 1010.
16. Skeie GO, Mygland A, Aarli JA, Gilhus NE. Titin antibodies in patients with late onset myasthenia gravis: clinical correlations. Autoimmunity 1995 20 : 99 104.
17. Lu CZ, Link H, Mo XA, Xiao BG, Zhang YL, Qin Z. Anti-presynaptic membrane receptor antibodies in myasthenia gravis. J Neurol Sci 1991 102 : 39 43.
18. Turner C. A review of myasthenia gravis: pathogenesis, clinical features and treatment. Curr Anaesth Crit Care 2007 18 : 15 23.
19. Potagas C, Dellatolas G, Tavernarakis A et al. Myasthenia gravis changes observed in a 30-years retrospective clinical study of a hospital-based population. J Neurol 2004 251 : 116 117.
20. Ishii W, Matsuda M, Hanyuda M et al. Comparison of the histological and immunohistochemical features of the thymus in young- and elderly-onset myasthenia gravis without thymoma. J Clin Neurosci 2007 14 : 110 115.
21. Yamamoto AM, Gajdos P, Eymard B et al. Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients. Arch Neurol 2001 58 : 885 890.
22. Chan KH, Cheung RT, Mak W, Ho SL. Nonthymoma early-onset- and late-onset-generalized myasthenia gravis - a retrospective hospital-based study. Clin Neurol Neurosurg 2007 109 : 686 691.
23. Romi F, Skeie GO, Aarli JA, Gilhus NE. The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies. Arch Neurol 2000 57 : 1596 1600.
24. Chen XJ, Qiao J, Lu CZ et al. The significance of titin antibodies in myasthenia gravis - correlation with thymoma and severity of myasthenia gravis. J Neurol 2004 251 : 1006 1011.
25. Shelton GD, Skeie GO, Kass PH, Aarli JA. Titin and ryanodine receptor autoantibodies in dogs with thymoma and late-onset myasthenia gravis. Vet Immunol Immunopathol 2001 78 : 97 105.
26. Aarli JA, Stefansson K, Marton LS, Wollmann RL. Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin. Clin Exp Immunol 1990 82 : 284 288.
27. Mix E, Goertsches R, Zett UK. Immunoglobulins - basic considerations. J Neurol 2006 253 (Suppl 5 V9 17.
28. Aarli JA, Romi F et al. Myasthenia gravis in individuals over 40. Ann N Y Acad Sci 2003 998 : 424 431.
29. Romi F, Skeie GO, Gilhus NE, Aarli JA. Striational antibodies in myasthenia gravis: reactivity and possible clinical significance. Arch Neurol 2005 62 : 442 446.
30. Romi F, Skeie GO, Vedeler C, Aarli JA, Zorzato F, Gilhus NE. Complement activation by titin and ryanodine receptor autoantibodies in myasthenia gravis. A study of IgG subclasses and clinical correlations. J Neuroimmunol 2000 111 : 169 176.
31. Limburg PC, The TH, Hummel-Tappel E, Oosterhuis HJ. Anti-acetylcholine receptor antibodies in myasthenia gravis. Part1: relation to clinical parameters in 250 patients. J Neurol Sci 1983 58 : 357 370.
32. Skeie GO, Aarli JA, Gilhus NE. Titin and ryanodine receptor antibodies in myasthenia gravis. Acta Neurol Scand Suppl 2006 183 : 19 23.
33. Zhu KY, Feferman T, Maiti PK, Souroujon MC, Fuchs S. Intravenous immunoglobulin suppresses experimental myasthenia gravis: immunological mechanisms. J Neuroimmunol 2006 176 : 187 197.
34. Stangel M, Pul R. Basic principles of intravenous immunoglobulin (IVIg) treatment. J Neurol 2006 253 (Suppl. 5 V18 24.
35. Fuchs S, Feferman T, Meidler R et al. Immunosuppression of EAMG by IVIg is mediated by a disease-specific anti-immunoglobulin fraction. Ann N Y Acad Sci 2008 1132 : 244 248.
36. Fuchs S, Feferman T, Zhu KY et al. Suppression of experimental autoimmune myasthenia gravis by intravenous immunoglobulin and isolation of a disease-specific IgG fraction. Ann N Y Acad Sci 2007 1110 : 550 558.
37. Feasby T, Banwell B, Benstead T et al. Guidelines on the use of intravenous immune globulin for neurologic conditions. Transfus Med Rev 2007 21 (2 Suppl. 1 S57 107.
38. Weinstein R. Therapeutic apheresis in neurological disorders: a survey of the evidence in support of current category I and II indications for therapeutic plasma exchange. J Clin Apher 2008 23 : 196 201.
39. Lehmann HC, Hartung HP, Meyer Zu Horste G, Kieseier BC. Plasma exchange in immune-mediated neuropathies. Curr Opin Neurol 2008 21 : 547 554.
40. Kuks JB, Skallebaek D. Plasmapheresis in Myasthenia Gravis. A survey. Transfus Sci 1998 19 : 129 136.
41. Zisimopoulou P, Lagoumintzis G, Kostelidou K et al. Towards antigen-specific apheresis of pathogenic autoantibodies as a further step in the treatment of myasthenia gravis by plasmapheresis. J Neuroimmunol 2008 201 202 : 95 103.
42. Yang L, Cheng Y, Yan WR, Yu YT. Extracorporeal whole blood immunoadsorption of autoimmune myasthenia gravis by cellulose tryptophan adsorbent. Artif Cells Blood Substit Biotechnol 2004 32 : 519 528.
43. Chiu HC, Chen WH, Yeh JH. The six year experience of plasmapheresis in patients with myasthenia gravis. Ther Apher 2000 4 : 291 295.
44. Yeh JH, Chiu HC. Comparison between double-filtration plasmapheresis and immunoadsorption plasmapheresis in the treatment of patients with myasthenia gravis. J Neurol 2000 247 : 510 513.